Stock GNPX GENPREX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Genprex, Inc.

Equities

GNPX

US3724462037

Delayed Nasdaq
Other stock markets
 20:04:15 29/04/2024 BST 		5-day change 1st Jan Change
2.18 USD -1.36% Intraday chart for Genprex, Inc. +0.79% -76.30%
04-03 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer CI
04-02 Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System CI

Evolution of the average Target Price on Genprex, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8128.4y9DmF-Pbw7igbjsDu4QhIX01ohex73vQtXbmmGvp0E.tmAS_zLXA22Rxc7dNtk95-ebj_4foeSrFuewzRDu9g2iYDnIKeIJVI3A2w~064c96228d78178fe6a9351f034a504d

Analyst Recommendations on Genprex, Inc.

HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target MT
Dawson James Initiates Genprex at Buy Rating With $3 Price Target MT
GENPREX : National Securities Starts Genprex at Buy With $7 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.21 USD
Average target price
165 USD
Spread / Average Target
+7,366.06%
High Price Target
320 USD
Spread / Highest target
+14,379.64%
Low Price Target
10 USD
Spread / Lowest Target
+352.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genprex, Inc.

HC Wainwright
Dawson James
National Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GNPX Stock
  4. Consensus Genprex, Inc.